Is Your Paper Ready for JAMA? Evidence-Based Medicine at Its Most Selective
Pre-submission guide for JAMA covering general-medicine fit, structured abstract rules, and how the journal differs from NEJM.
Senior Researcher, Oncology & Cell Biology
Author context
Specializes in manuscript preparation and peer review strategy for oncology and cell biology, with deep experience evaluating submissions to Nature Medicine, JCO, Cancer Cell, and Cell-family journals.
Next step
Choose the next useful decision step first.
Use the guide or checklist that matches this page's intent before you ask for a manuscript-level diagnostic.
JAMA occupies a distinctive position among top medical journals. While NEJM focuses tightly on practice-changing clinical trials and The Lancet emphasizes global health policy, JAMA casts a wider net. It publishes clinical research, public health, health policy, epidemiology, and medical education. That broader scope sounds like an advantage for authors, but it creates its own challenge: JAMA receives submissions from across all of medicine, and its 5% acceptance rate reflects brutal selectivity across every category.
JAMA's editorial scope: broader than you think
Most researchers think of JAMA as a clinical trials journal. It is, but it's also much more. JAMA regularly publishes:
- Randomized controlled trials with patient-centered outcomes
- Large observational studies and prospective cohorts
- Health policy analyses and health systems research
- Clinical epidemiology and population health studies
- Health disparities research
- US health system analyses
- Preventive medicine and screening studies
- Medical education research (though this is rarer in the flagship)
This breadth means your paper doesn't need to be a phase III trial to get into JAMA. A well-designed cohort study examining health disparities across racial groups, or a policy analysis showing that a screening program reduces cancer mortality, can absolutely clear the desk. But the bar within each category is high.
Metric | Value |
|---|---|
Impact Factor (2024 JCR) | 55.0 |
Acceptance rate | ~5% |
Desk rejection rate | ~80% |
Annual submissions | ~7,000-8,000 |
Structured abstract limit | 350 words |
Key Points box | 75-100 words (required) |
Submission system | JAMA Network portal |
JAMA Network specialty journals | 13 |
What desk editors are screening for
JAMA's desk rejection rate of approximately 80% means four out of five papers never reach a reviewer. The editorial screening focuses on three dimensions:
Clinical or public health significance at scale. JAMA wants studies whose findings affect how physicians practice or how health systems operate for large patient populations. A trial showing that drug A beats drug B for a common condition clears this bar. A pilot study suggesting that a novel intervention might work in a small subgroup doesn't.
Methodological rigor appropriate to the question. JAMA's editors are evidence-based medicine experts. They'll spot design flaws in the abstract. If you're reporting a treatment comparison without randomization and don't have a compelling justification (natural experiment, regression discontinuity, instrumental variable), the desk rejection will mention study design.
Relevance to JAMA's readership. JAMA's audience is heavily weighted toward US-based physicians, including internists, family medicine physicians, and generalists. Research that's highly specialized or relevant only to non-US health systems may be redirected to a JAMA Network specialty journal or The Lancet.
The structured abstract: JAMA's format is different
JAMA uses a structured abstract format that's distinct from NEJM's and The Lancet's. The maximum length is 350 words, and the required headings are:
- Importance: Why this study matters. Not background information, but the specific clinical or public health gap this study addresses.
- Objective: What the study aimed to test or evaluate. One sentence is ideal.
- Design, Setting, and Participants: Study type, where it was done, who was included. Be specific about enrollment dates and eligibility criteria.
- Interventions: What was tested (for intervention studies) or what exposure was examined.
- Main Outcomes and Measures: Primary endpoint and how it was measured.
- Results: Key findings with effect sizes, confidence intervals, and p-values.
- Conclusions and Relevance: What the findings mean for clinical practice or health policy. Not a restatement of results.
JAMA also requires a Key Points box of 75-100 words summarizing the question, findings, and meaning. This is separate from the abstract and appears prominently in the published article. Editors read this during triage, so don't treat it as an afterthought.
The "Importance" heading deserves attention. Most journals start with "Background" or "Context." JAMA's choice of "Importance" is deliberate. They want you to justify why this study needed to be done, not describe what's already known. If your Importance section reads like a literature review, rewrite it.
How JAMA's review process works
Papers that clear the desk enter a review process with several distinctive features:
Multiple reviewer types. JAMA typically assigns two to three clinical experts plus, often, a statistical reviewer. For some papers, JAMA also invites a patient or policy reviewer when the study has direct implications for patient care or health systems.
Structured review forms. JAMA reviewers complete detailed forms assessing specific aspects of the paper: importance of the research question, appropriateness of the study design, adequacy of the statistical analysis, clarity of reporting, and clinical significance of the findings. This structured approach means reviews tend to be systematic and thorough.
Reporting guideline enforcement. JAMA strictly enforces CONSORT (RCTs), STROBE (observational), PRISMA (systematic reviews), STARD (diagnostic accuracy), and other reporting guidelines. Incomplete reporting checklists can delay your paper or trigger return for revision before review even begins.
Open data expectations. JAMA has increasingly emphasized data sharing. For clinical trials, you'll be asked to provide a data sharing statement and, in many cases, to make individual participant data available to qualified researchers within a specified timeframe.
Review stage | Typical timeline |
|---|---|
Desk review | 1-3 weeks |
Peer review | 4-6 weeks |
Statistical review | Concurrent |
Revision period | 4-8 weeks |
Second review | 2-4 weeks |
Total (submission to acceptance) | 4-8 months |
The JAMA Network: your backup plan
JAMA's biggest structural advantage for authors is the JAMA Network, which includes 13 specialty journals:
JAMA Internal Medicine, JAMA Oncology, JAMA Cardiology, JAMA Neurology, JAMA Psychiatry, JAMA Surgery, JAMA Dermatology, JAMA Ophthalmology, JAMA Otolaryngology, JAMA Pediatrics, JAMA Network Open, JAMA Health Forum, and others.
When JAMA rejects a paper, editors can recommend transfer to a specific JAMA Network journal. The reviewer reports travel with the manuscript, which can shorten the review process at the receiving journal significantly. JAMA Network Open, in particular, has become a strong landing spot for methodologically sound papers that don't meet the flagship's significance threshold.
This cascade makes JAMA a reasonable first-attempt journal even for specialty-focused research. If the work is important enough for the specialty audience, the JAMA Network journal may accept it with the benefit of existing reviews. If it's important enough for the general medical audience, JAMA itself will consider it.
JAMA vs. NEJM vs. The Lancet: choosing the right target
These three journals are the pinnacle of general medical publishing, but they have different editorial personalities:
Feature | JAMA | NEJM | The Lancet |
|---|---|---|---|
IF (2024) | 63.1 | 78.5 | 98.4 |
Editorial focus | Evidence-based medicine broadly | Clinical practice change | Global health and policy |
Readership | US physicians, generalists | Specialists, internists | Global clinicians, policymakers |
Health policy | Strong coverage | Limited | Very strong |
Disparities research | Strong | Moderate | Strong (global equity) |
Speed to decision | 4-6 weeks | 21 days median | 4-8 weeks |
Cascade network | 13 specialty journals | Nature portfolio | Lancet specialty journals |
Choose JAMA when your paper addresses a clinical or public health question relevant to a broad physician audience, has strong methodology, and you value the JAMA Network as a backup. JAMA is particularly strong for health disparities research, preventive medicine, and health policy studies that other top journals might not prioritize.
Choose NEJM when your paper is a large clinical trial with hard endpoints that will change treatment guidelines. NEJM's 21-day decision time makes it worth trying first if you think your paper has a shot.
Choose The Lancet when your paper has a global health dimension, especially if it involves research from low- and middle-income countries or has direct health policy implications beyond clinical practice.
Honest self-assessment
Before preparing a JAMA submission, ask yourself:
Is this study important enough for a general medical audience? JAMA's readers span all of medicine. If your paper matters only to cardiologists, it belongs in JAMA Cardiology or Circulation. If it matters to all physicians, or to the health system broadly, JAMA is appropriate.
Does the methodology match the question? JAMA's editors are methodological purists. If a randomized trial was feasible and you did an observational study instead, you'll need a strong justification. If you used a novel analytical approach, make sure it's validated.
Have you completed the Key Points box? This 75-100 word summary is required at submission and reviewed during triage. Many authors skip it or write it carelessly. Don't. It's one of the first things editors read.
Is your abstract structured correctly? JAMA's headings (Importance, Objective, Design/Setting/Participants, etc.) are specific. If you're repurposing an abstract written for another journal, adjust the headings and content to match JAMA's format exactly.
Have you attached all reporting checklists? CONSORT, STROBE, PRISMA, or whatever applies to your study design. Missing checklists delay processing and suggest carelessness.
A Manusights pre-submission review can help evaluate whether your manuscript's clinical significance and methodological presentation align with JAMA's specific editorial priorities before you submit.
Bottom line
JAMA's 5% acceptance rate hides a broader editorial appetite than NEJM or The Lancet. If your paper is a strong clinical trial, great. But JAMA also takes health policy, epidemiology, disparities research, and population health studies that wouldn't fit NEJM's clinical focus. The JAMA Network provides a safety net that makes the flagship journal worth attempting even when you're uncertain about fit. Just make sure your abstract uses JAMA's format, your methodology is bulletproof, and your Key Points box makes the case in 100 words or fewer.
- Manusights local fit and process context from JAMA acceptance rate, JAMA under review, and JAMA Oncology cover letter.
Sources
- Official submission guidance from JAMA instructions for authors and JAMA Network editorial requirements.
Reference library
Use the core publishing datasets alongside this guide
This article answers one part of the publishing decision. The reference library covers the recurring questions that usually come next: how selective journals are, how long review takes, and what the submission requirements look like across journals.
Dataset / reference guide
Peer Review Timelines by Journal
Reference-grade journal timeline data that authors, labs, and writing centers can cite when discussing realistic review timing.
Dataset / benchmark
Biomedical Journal Acceptance Rates
A field-organized acceptance-rate guide that works as a neutral benchmark when authors are deciding how selective to target.
Reference table
Journal Submission Specs
A high-utility submission table covering word limits, figure caps, reference limits, and formatting expectations.
Before you upload
Choose the next useful decision step first.
Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.
Use the scan once the manuscript and target journal are concrete enough to evaluate.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Supporting reads
Conversion step
Choose the next useful decision step first.
Use the scan once the manuscript and target journal are concrete enough to evaluate.